According to related industries, news of approval for the expansion of domestic indications of cancer immunotherapy Opdivo (Nivolumab) and Keytruda (Pembrolizumab) in PD-1 inhibition mechanisms continues. Although it is the same mechanism, it is competing by securing different indications. In the case of Opdivo, two postoperative adjuvant therapy and three combined therapy indications were added.

Postoperative adjuvant therapy in patients with esophageal cancer or gastroesophageal junction cancer with residual pathological diseases after receiving chemotherapy (CRT) as a preoperative adjuvant therapy and Postoperative adjuvant therapy in patients with root resection were added.

Combinatio